These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 27194727)

  • 1. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.
    Brumatti G; Ma C; Lalaoui N; Nguyen NY; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; de Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J
    Sci Transl Med; 2016 May; 8(339):339ra69. PubMed ID: 27194727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
    Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
    Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.
    Chromik J; Safferthal C; Serve H; Fulda S
    Cancer Lett; 2014 Mar; 344(1):101-109. PubMed ID: 24184825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents.
    Carter BZ; Mak PY; Mak DH; Shi Y; Qiu Y; Bogenberger JM; Mu H; Tibes R; Yao H; Coombes KR; Jacamo RO; McQueen T; Kornblau SM; Andreeff M
    J Natl Cancer Inst; 2014 Feb; 106(2):djt440. PubMed ID: 24526787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic-induced necroptosis.
    Uzunparmak B; Gao M; Lindemann A; Erikson K; Wang L; Lin E; Frank SJ; Gleber-Netto FO; Zhao M; Skinner HD; Newton J; Sikora AG; Myers JN; Pickering CR
    JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33108350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis.
    Laukens B; Jennewein C; Schenk B; Vanlangenakker N; Schier A; Cristofanon S; Zobel K; Deshayes K; Vucic D; Jeremias I; Bertrand MJ; Vandenabeele P; Fulda S
    Neoplasia; 2011 Oct; 13(10):971-9. PubMed ID: 22028622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL.
    McComb S; Aguadé-Gorgorió J; Harder L; Marovca B; Cario G; Eckert C; Schrappe M; Stanulla M; von Stackelberg A; Bourquin JP; Bornhauser BC
    Sci Transl Med; 2016 May; 8(339):339ra70. PubMed ID: 27194728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
    Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
    Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells.
    Steinwascher S; Nugues AL; Schoeneberger H; Fulda S
    Cancer Lett; 2015 Sep; 366(1):32-43. PubMed ID: 26028172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smac mimetic triggers necroptosis in pancreatic carcinoma cells when caspase activation is blocked.
    Hannes S; Abhari BA; Fulda S
    Cancer Lett; 2016 Sep; 380(1):31-8. PubMed ID: 27267809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smac mimetics and type II interferon synergistically induce necroptosis in various cancer cell lines.
    Cekay MJ; Roesler S; Frank T; Knuth AK; Eckhardt I; Fulda S
    Cancer Lett; 2017 Dec; 410():228-237. PubMed ID: 28923396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
    Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
    BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker profile for prediction of response to SMAC mimetic monotherapy in pediatric precursor B-cell acute lymphoblastic leukemia.
    Zinngrebe J; Schlichtig F; Kraus JM; Meyer M; Boldrin E; Kestler HA; Meyer LH; Fischer-Posovszky P; Debatin KM
    Int J Cancer; 2020 Jun; 146(11):3219-3231. PubMed ID: 31749151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis.
    Steinhart L; Belz K; Fulda S
    Cell Death Dis; 2013 Sep; 4(9):e802. PubMed ID: 24030154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways.
    Tanzer MC; Khan N; Rickard JA; Etemadi N; Lalaoui N; Spall SK; Hildebrand JM; Segal D; Miasari M; Chau D; Wong WL; McKinlay M; Chunduru SK; Benetatos CA; Condon SM; Vince JE; Herold MJ; Silke J
    Cell Death Differ; 2017 Mar; 24(3):481-491. PubMed ID: 28106882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells.
    Gerges S; Rohde K; Fulda S
    Cancer Lett; 2016 May; 375(1):127-132. PubMed ID: 26944210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NCTD promotes Birinapant-mediated anticancer activity in breast cancer cells by downregulation of c-FLIP.
    Zhao L; Yang G; Bai H; Zhang M; Mou D
    Oncotarget; 2017 Apr; 8(16):26886-26895. PubMed ID: 28460471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.
    Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C
    Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.